IRD

Opus Genetics, Inc.

Opus Genetics, Inc. (IRD) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Profitability (D). The rating has held at C for 2 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
C+
Factor Score 2.7 / 5.0
Growth
C-
Factor Score 1.9 / 5.0
Profitability
D
Factor Score 1.3 / 5.0
Momentum
B
Factor Score 3.2 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -5.8
EV / EBITDA -5.9
Rev Growth YoY -63.1%
Gross Margin 0.0%
Price Return 3M 15.9%
Price Return 12M 118.8%
Catalyst Signal 0.00
Market Cap $412.9M
TTM Revenue $7.9M
Price / Sales 52.2
ROE N/M

Historical Factor Score Progression

Held C for 2 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 C+ (2.7) C- (1.9) D (1.3) B (3.2) C+ (2.6) C (2.3)
2026-11-05 C+ (2.8) D+ (1.6) C- (2.0) B (3.2) C+ (2.7) C (2.4)
2026-10-29 C+ (2.8) D+ (1.5) C- (2.1) B- (3.1) C+ (2.7) C (2.5)
2026-10-22 C+ (2.8) D+ (1.5) C- (2.1) B+ (3.7) C+ (2.6) C+ (2.6)
2026-10-15 C+ (2.8) D+ (1.6) C- (2.1) B+ (3.6) C+ (2.6) C+ (2.5)
Page 1 of 4